Przejdź do treści

Filtry

Dane naukowe

Podręcznik/instrukcje

Aktualności

Vaccines for preventing tick-borne encephalitis

Także dostęne w

Tick-borne encephalitis (TBE) is a disease of the central nervous system caused by a tick-borne viral infection. TBE can lead to severe neurological syndromes, which can result in death. Many species of wild and domestic animals act as hosts of ticks; transmission to humans occurs often in woodland areas, especially during the summer, which is the time of greatest human outdoor activity. TBE is particularly prevalent in Central and Eastern Europe.

Although personal protective measures to avoid tick bites (such as insect repellents, avoidance of tick-infested areas, and use of protective clothing) are recommended, there is no effective treatment for TBE, and vaccination is the only preventive measure currently available.

This review evaluates the effectiveness and adverse events induced by current vaccines for preventing TBE. The authors identified 11 trials involving 8184 participants, which assessed different versions of three types of tick-borne encephalitis vaccines. No trials reported on cases of clinical TBE, but all tested vaccines were highly immunogenic. Adverse effects were commonly reported, none were serious or life threatening.

The authors recommend further trials or well-conducted observational studies with clinical outcomes (ie TBE cases) to better estimate vaccine effectiveness and the duration of vaccine protection, as well as long-term adverse events.

Wprowadzenie

Tick-borne encephalitis (TBE) is a disease of the central nervous system caused by a tick-borne viral infection. TBE can lead to severe neurological syndromes such as meningitis, meningoencephalitis, and meningoencephalomyelitis, which can result in death. There is no treatment, and prevention with the vaccine is the only intervention currently available.

Cele

To evaluate vaccines for preventing TBE in terms of effectiveness and adverse effects.

Metody wyszukiwania badań

In June 2008, we searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library 2008, Issue 2), MEDLINE, EMBASE, LILACS, and mRCT. We also checked reference lists of articles.

Kryteria doboru badań

Randomized and quasi-randomized controlled trials comparing TBE vaccines against placebo, control vaccines, no intervention, or a different dose or schedule of the intervention vaccine.

Zbieranie i analiza danych

Two authors applied the inclusion criteria, extracted data, and assessed each trial's risk of bias. We could not combine the included trials in a meta-analysis because of differences in comparisons and outcomes.

Główne wyniki

Eleven trials (corresponding to 10 papers) involving 8184 participants (6586 adults and 1598 children) were included. Different versions of three types of TBE vaccines were tested (IPVE, FSME-IMMUN, and Encepur); out of which only three (Encepur children, Encepur Adults, and FSME-IMMUN "new") are currently licensed. No trials reported on cases of clinical TBE, but all reported on antibody titre (seroconversion). All the vaccines gave seroconversion rates of over 87%. Systemic and local adverse effects were common; none were severe or life threatening.

Wnioski autorów

Tick-borne encephalitis vaccines appear to be highly immunogenic, but the relationship between seroconversion and clinical protection has not been established. Although adverse effects were commonly reported, none were serious or life threatening.

Cytowanie
Demicheli V, Debalini MG, Rivetti A. Vaccines for preventing tick-borne encephalitis. Cochrane Database of Systematic Reviews 2021, Issue 8. Art. No.: CD000977. DOI: 10.1002/14651858.CD000977.pub2.

Używamy plików cookie

Używamy niezbędnych plików cookie, aby nasza strona mogła działać. Chcielibyśmy również ustawić opcjonalne pliki cookie do analizy, aby pomóc nam udoskonalić tę stronę. Nie będziemy ustawiać opcjonalnych plików cookie, chyba że je włączysz. Użycie tego narzędzia spowoduje ustawienie pliku cookie na Twoim urządzeniu, aby zapamiętać Twoje preferencje. W każdej chwili możesz zmienić swoje preferencje dotyczące plików cookie, klikając na link "Ustawienia plików cookie" znajdujący się w stopce każdej strony.
Bardziej szczegółowe informacje na temat używanych przez nas plików cookie można znaleźć na naszej stronieStrona plików cookies

Zaakceptuj wszystkie
Skonfiguruj